Democratic mayoral nominee Zohran Mamdani said he would drop a Holocaust remembrance group’s definition of “antisemitism” if he becomes mayor — a turnaround in police that has some Jewish rights ...

The FDA approved oral rilzabrutinib (Wayrilz) for treating persistent or chronic immune thrombocytopenia (ITP), the agency announced on Tuesday. As the first Bruton's tyrosine kinase (BTK) inhibitor ...

Wayrilz is the first BTK inhibitor approved for ITP, showing significant platelet count improvements and faster response times in the LUNA 3 trial. The LUNA 3 trial demonstrated a 23% durable platelet ...

Please provide your email address to receive an email when new articles are posted on . Patients who received rilzabrutinib had a statistically significant durable platelet response vs. placebo.

Novel treatment targets BTK through multi-immune modulation to help address root causes of ITP Approval based on LUNA 3 phase 3 study that demonstrated rapid and durable platelet response and ...

This article is part of Run, Die, Repeat, Polygon's week-long series exploring roguelikes. The definition of "roguelike" is one of those topics of conversation that will keep die-hard fans debating ...

An expert discusses treatment strategies for immune thrombocytopenic purpura (ITP), emphasizing individualized decisions based on platelet count, bleeding symptoms, and comorbidities, with options ...

Doptelet is approved for pediatric thrombocytopenia, offering a new sprinkle formulation for children under six years old. The AVA-PED-301 study showed 27.8% achieved durable platelet response, with ...

About half of people with ITP say the condition affects their emotional and psychological health, and about one-third of them say it causes them to feel self-conscious about their appearance. Moreover ...

If you have immune thrombocytopenia (ITP) and are struggling with fatigue, you’re not alone. In an international survey of 1,507 people with ITP, as many as 73 percent reported fatigue as their most ...

A Prescription Drug User Fee Act target date of July 24, 2025 has been set for the sNDA application. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) ...

Platelets are special blood cells tasked with preventing too much blood loss. These small and colorless structures are also known as thrombocytes and resemble cell fragments. Your body has three types ...